The Pharmacokinetics and Safety of IDV/r With NRTIs in HIV/TB Co-infected Patients Receiving Rifampicin

Overview

We believe that there is a strong rationale for the study of IDV/r 600/100 bid as a boosted-PI combination that, in the presence of RMP, is able to produce a satisfactory PK profile associated with adequate antiretroviral potency, tolerability and efficacy.

Full Title of Study: “The Pharmacokinetics and Safety of Ritonavir-boosted Indinavir 600/100mg Bid Combined With NRTIs in ARV na├»ve HIV/TB Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 2008

Detailed Description

The fixed-dose combination of d4T+3TC+NVP (GPOvir) has been widely used in Thailand since June 2002. The prevalence of NNRTI resistance has increased since 2005. Efavirenz-based antiretroviral therapy (ART) is preferred in patients with TB/HIV receiving rifampin-containing TB regimens. However, efavirenz cannot be used in the context of NNRTI failure, intolerance or toxicity. The optimal ART in populations receiving rifampicin remains unknown. Rifabutin, which is recommended in combination with a boosted protease inhibitor (PI/r) is expensive and not available in Thailand and other developing countries. Ritonavir-boosted indinavir (IDV/r) is potent and the cheapest boosted PI available in Thailand. If IDV/r in combination with rifampin demonstrates suitable pharmacokinetics and is well tolerated, this regimen might prove useful and could be widely implemented. However, high rates of gastrointestinal and renal toxicity have been demonstrated in Thai patients receiving standard doses of IDV/r 800/100 BID. We believe that there is a strong rationale to study if IDV/r 600/100 BID in combination with rifampin is able to produce a satisfactory pharmacokinetic profile, with antiretroviral potency, tolerability and efficacy.

Interventions

  • Drug: indinavir/ritonavir
    • IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks

Arms, Groups and Cohorts

  • Other: 1
    • IDV/r 600/100 mg + rifampicin

Clinical Trial Outcome Measures

Primary Measures

  • pharmacokinetics of ritonavir-boosted indinavir 600/100mg bid in combination with rifampicin-containing anti-TB therapy.
    • Time Frame: 2 weeks

Secondary Measures

  • safety of ritonavir-boosted indinavir 600/100mg bid in combination with rifampicin-containing anti-TB therapy
    • Time Frame: 48 weeks
  • efficacy of ritonavir-boosted indinavir 600/100mg bid in combination with rifampicin-containing anti-TB therapy
    • Time Frame: 48 weeks
  • the prevalence of immune recovery syndrome of TB and other HIV-related conditions after ritonavir-boosted indinavir 600/100mg bid
    • Time Frame: 48 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Confirmed HIV positive after voluntary counselling and testing – Aged between 18 and 60 years of age – Antiretroviral treatment naive – CD4+ cell count of <200 cells/mm3 at the time of TB diagnosis – ALT <5 times ULN – Serum creatinine <1.4 mg/dl – Haemoglobin >8 mg/L – TB diagnosis; either probable (clinical symptoms plus chest x-ray and response to anti-TB medication) or definitive( sputum AFB culture confirmed) and receiving or planning to receive rifampicin-containing anti-TB therapy for at least a 2 week period before the initiation of ART – No other active OI (CDC class C event) – Able to provide written informed consent Exclusion Criteria:

  • Current use of steroids and other immunosuppressive agents – Current use of any prohibited medications related to compliance and drug pharmacokinetics – Patients with current alcohol or illicit substance use that in the opinion of the site Principal Investigator would conflict with any aspect of the conduct of the trial. – Previous exposure to nevirapine monotherapy – Unlikely to be able to remain in follow-up for the protocol defined period – Patients with proven or suspected acute hepatitis. Patients with chronic viral hepatitis are eligible provided ALT, AST < 5 x ULN. – Karnofsky performance score <30%

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • The HIV Netherlands Australia Thailand Research Collaboration
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Kiat Ruxrungtham, MD, Principal Investigator, HIV-NAT, Thai Red Cross AIDS Research Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.